Filter
Period
Filter by
recent search
Showing: 1 – 05 of 110 Regulated Information
Ipsen – Half year statement – 2022 12 31
This article or press release has no online content. Please download the associated documents for more information.
Voting rights on 31 December 2022
This article or press release has no online content. Please download the associated documents for more information.
Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva
PARIS, FRANCE, 23 December 2022 – The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application for palovarotene, an investigational treatment for the reduction of new abnormal bone formation (heterotopic ossification) in people…
Voting rights on 30 November 2022
This article or press release has no online content. Please download the associated documents for more information.
Voting rights on 31 October 2022
This article or press release has no online content. Please download the associated documents for more information.